GlassScriptPhysician profile
Amit M Patel
NPI 1811153604
$5,250.79
in general payments reported to CMS, 2019-2025
34 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,020 · 2020: $865 · 2021: $1,058 · 2022: $394 · 2023: $53.83 · 2024: $543 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,418.33 | 2019-2025 | Proclaim, Prodigy |
| Medtronic Vascular, INC. | $1,329.17 | 2019 | |
| Boston Scientific Corporation | $398.61 | 2019-2025 | Na |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.61 | 2019-2025 | Relistor |
| Medtronic USA, INC. | $84.91 | 2019-2020 | |
| Stryker Corporation | $79.01 | 2021 | |
| Protega Pharmaceutials INC | $78.32 | 2025 | Roxybond |
| Vertiflex, INC. | $77.72 | 2019 | |
| Amgen INC. | $59.82 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $51.04 | 2021 | |
| Collegium Pharmaceutical, INC. | $48.98 | 2019-2022 | |
| Electronic Waveform Lab, INC. | $41.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $40.44 | 2019 | |
| Indivior INC. | $40.15 | 2025 | Sublocade |
| Saluda Medical Americas, INC. | $40.02 | 2024 | Evoke |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthogenrx INC. | $33.11 | 2019 | |
| Grt US Holding, INC. | $30.73 | 2020-2021 | |
| Tersera Therapeutics LLC | $29.18 | 2022 | |
| Allergan, INC. | $27.81 | 2022 | |
| Vertos Medical, INC. | $24.90 | 2020 | |
| Zoll Respicardia, INC. | $22.08 | 2023 | Remede System |
| Ultragenyx Pharmaceutical INC. | $20.83 | 2021 | |
| Nalu Medical, INC. | $20.47 | 2021 | |
| Ethicon US, LLC | $20.11 | 2019 | |
| Bioventus LLC | $19.83 | 2019 | |
| Redhill Biopharma INC. | $19.59 | 2020 | |
| Spr Therapeutics, INC | $19.08 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.02 | 2022 | |
| Otto Bock Healthcare LP | $13.31 | 2021 | |
| Companion Medical, INC. | $12.60 | 2020 | |
| Scilex Pharmaceuticals INC. | $12.15 | 2019 | |
| Pfizer INC. | $11.57 | 2019 | |
| Biodelivery Sciences International, INC. | $11.50 | 2019 | |
| Forte Bio-Pharma LLC | $7.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.